Recursion Pharmaceuticals
RXRX
RXRX
128 hedge funds and large institutions have $680M invested in Recursion Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.39% less ownership
Funds ownership: 59.14% → 58.75% (-0.39%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
58% less capital invested
Capital invested by funds: $1.62B → $680M (-$935M)
Holders
128
Holding in Top 10
6
Calls
$321K
Puts
$278K
Top Buyers
| 1 | +$5.09M | |
| 2 | +$4.96M | |
| 3 | +$4.75M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.41M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.26M |
Top Sellers
| 1 | -$19.6M | |
| 2 | -$7.02M | |
| 3 | -$7M | |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$6.32M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.11M |